.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,754,123

« Back to Dashboard

Claims for Patent: 8,754,123

Title:Pharmaceutical compositions having desirable bioavailability
Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
Inventor(s): Kabra; Bhagwati P. (Euless, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:13/442,475
Patent Claims: 1. An aqueous ophthalmic pharmaceutical solution composition suitable for topical application to an eye of a human, comprising: a prostaglandin suitable for lowering intraocular pressure of the eye, the prostaglandin being in the composition at a concentration that is at least 0.001 w/v % but less than 0.01 w/v %; a surfactant in the composition at a concentration that is at least 0.03 w/v % but less than 0.3 w/v %, wherein: i. the surfactant is entirely ethoxylated and/or hydrogenated vegetable oil and the ethoxylated and/or hydrogenated castor oil is the only surfactant in the composition; and ii. the composition is free of benzalkonium chloride; and a polymeric quaternary ammonium compound in the composition at a concentration that is greater than 0.0003 w/v % but less than 0.003 w/v %; and water.

2. A composition as in claim 1 wherein concentration of the surfactant in the composition is less than 0.15 w/v %.

3. A composition as in claim 1 wherein the prostaglandin is travoprost.

4. A composition as in claim 1 wherein the prostaglandin and the surfactant are non-ionic.

5. A composition as in claim 1 wherein the surfactant is entirely ethoxylated or hydrogenated vegetable oil.

6. A composition as in claim 1 wherein the surfactant is entirely castor oil.

7. A composition as in claim 1 wherein the surfactant is entirely Polyoxyl 40 Hydrogenated castor Oil.

8. A composition as in claim 1 wherein the composition satisfies Ph. Eur. A, Ph. Eur. B or both.

9. A composition as in claim 1 wherein the composition is substantially free of any chloride containing agents.

10. A composition as in claim 1 wherein the prostaglandin is in the composition at a concentration of less than 0.006 w/v %.

11. A composition as in claim 1 wherein the composition is disposed in an eye dropper.

12. A composition as in claim 4 wherein the surfactant is entirely ethoxylated and/or hydrogenated vegetable oil.

13. A composition as in claim 12 wherein the surfactant is entirely castor oil.

14. A composition as in claim 13 wherein the prostaglandin is in the composition at a concentration of less than 0.006 w/v %.

15. A composition as in claim 14 wherein the composition satisfies Ph. Eur. A, Ph. Eur. B or both.

16. A composition as in claim 14 wherein the prostaglandin is travoprost.

17. A composition as in claim 16 wherein the surfactant is entirely Polyoxyl 40 Hydrogenated castor Oil.

18. A composition as in claim 17 wherein the composition is disposed in an eye dropper.

19. A composition as in claim 18 wherein concentration of the surfactant in the composition is less than 0.15 w/v %.

20. A composition as in claim 18 wherein concentration of the polymeric quaternary ammonium compound in the composition is greater than 0.0007 w/v % but less than 0.0015 w/v % of the pharmaceutical composition.

21. A composition as in claim 1 wherein concentration of the polymeric quaternary ammonium compound in the composition is greater than 0.0007 w/v % but less than 0.0015 w/v % of the pharmaceutical composition.

22. A composition as in claim 1 wherein the polymeric quaternary ammonium compound is polyquaternium-1.

23. A composition as in claim 20 wherein the polymeric quaternary ammonium compound is polyquaternium-1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc